CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells. Qadir, A. S., Guégan, J. P., Ginestier, C., Chaibi, A., Bessede, A., Charafe-Jauffret, E., Macario, M., Lavoué, V., Rouge, T. D. L. M., Law, C., Vilker, J., Wang, H., Stroup, E., Schipma, M. J., Bridgeman, B., Murmann, A. E., Ji, Z., Legembre, P., & Peter, M. E. iScience, 24(11):103348, November, 2021.
CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells [link]Paper  doi  abstract   bibtex   
The apoptosis inducing receptor CD95/Fas has multiple tumorigenic activities. In different genetically engineered mouse models tumor-expressed CD95 was shown to be critical for cell growth. Using a combination of immune-deficient and immune-competent mouse models, we now establish that loss of CD95 in metastatic triple negative breast cancer (TNBC) cells prevents tumor growth by modulating the immune landscape. CD95-deficient, but not wild-type, tumors barely grow in an immune-competent environment and show an increase in immune infiltrates into the tumor. This growth reduction is caused by infiltrating NK cells and does not involve T cells or macrophages. In contrast, in immune compromised mice CD95 k.o. cells are not growth inhibited, but they fail to form metastases. In summary, we demonstrate that in addition to its tumor and metastasis promoting activities, CD95 expression by tumor cells can exert immune suppressive activities on NK cells, providing a new target for immune therapy.
@article{qadir_cd95fas_2021,
	title = {{CD95}/{Fas} protects triple negative breast cancer from anti-tumor activity of {NK} cells},
	volume = {24},
	issn = {25890042},
	url = {https://linkinghub.elsevier.com/retrieve/pii/S2589004221013171},
	doi = {10.1016/j.isci.2021.103348},
	abstract = {The apoptosis inducing receptor CD95/Fas has multiple tumorigenic activities. In different genetically engineered mouse models tumor-expressed CD95 was shown to be critical for cell growth. Using a combination of immune-deficient and immune-competent mouse models, we now establish that loss of CD95 in metastatic triple negative breast cancer (TNBC) cells prevents tumor growth by modulating the immune landscape. CD95-deficient, but not wild-type, tumors barely grow in an immune-competent environment and show an increase in immune infiltrates into the tumor. This growth reduction is caused by infiltrating NK cells and does not involve T cells or macrophages. In contrast, in immune compromised mice CD95 k.o. cells are not growth inhibited, but they fail to form metastases. In summary, we demonstrate that in addition to its tumor and metastasis promoting activities, CD95 expression by tumor cells can exert immune suppressive activities on NK cells, providing a new target for immune therapy.},
	language = {en},
	number = {11},
	urldate = {2024-03-19},
	journal = {iScience},
	author = {Qadir, Abdul S. and Guégan, Jean Philippe and Ginestier, Christophe and Chaibi, Assia and Bessede, Alban and Charafe-Jauffret, Emmanuelle and Macario, Manon and Lavoué, Vincent and Rouge, Thibault De La Motte and Law, Calvin and Vilker, Jacob and Wang, Hongbin and Stroup, Emily and Schipma, Matthew J. and Bridgeman, Bryan and Murmann, Andrea E. and Ji, Zhe and Legembre, Patrick and Peter, Marcus E.},
	month = nov,
	year = {2021},
	pages = {103348},
	file = {Qadir et al. - 2021 - CD95Fas protects triple negative breast cancer fr.pdf:C\:\\Users\\lagad\\Zotero\\storage\\FGRU4RWJ\\Qadir et al. - 2021 - CD95Fas protects triple negative breast cancer fr.pdf:application/pdf},
}

Downloads: 0